Medicamen Biotech Ltd. (MEDICAM): Medicamen Biotech Share Price rises 8.86% as stock gains to Rs 346.40
- September 16, 2026
- Posted by: Harsh Piplani
- Category: News
Medicamen Biotech Share Price rose to Rs 346.40, up 8.86% today, with market capitalisation at Rs 438.76 crore. The move is confirmed by the day’s price data, while a company-specific catalyst is not established in the supplied record.
Medicamen Biotech Share Price moved higher today as Medicamen Biotech Ltd. closed at Rs 346.40, up Rs 28.20 or 8.86% from the previous close of Rs 318.20. The stock opened at Rs 317.95, touched an intraday high of Rs 346.40 and a low of Rs 297.25, with turnover of Rs 0.54 crore and market capitalisation of Rs 438.76 crore. The supplied data confirms the share price rise but does not establish a company-specific catalyst. For readers tracking Medicamen Biotech Share Price Today, the move is relevant because it places the stock among the day’s notable gainers in the Indian Stock Market context. Univest is covering the event as a factual stock news update, with the broader picture shaped by valuation, sector comparison and company fundamentals.
For investors searching Medicamen Biotech Share Price news today, the key point is simple: the stock is higher on the session, the price event is verified, and the next layer of analysis comes from fundamentals, sector benchmarks and peer comparison rather than any unconfirmed trigger. Univest presents the move in context so readers can assess Medicamen Biotech Share Price as both a same-day event and a stock analysis case.
Medicamen Biotech Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 346.4 |
| Previous Close | Rs 318.2 |
| Today's Move | Rs 28.2 (+8.86%) |
| Open | Rs 317.95 |
| High | Rs 346.4 |
| Low | Rs 297.25 |
| Turnover | Rs 0.54 crore |
| Market Capitalisation | Rs 438.76 crore |
| Market Cap Category | Micro Cap |
Medicamen Biotech Ltd. (MEDICAM) rose to Rs 346.4 from the previous close of Rs 318.2, a move of Rs 28.2 or 8.86%. The stock opened at Rs 317.95, reached a high of Rs 346.4, recorded a low of Rs 297.25.
Medicamen Biotech Share Price Today shows a clear same-day gain from Rs 318.20 to Rs 346.40, with the stock rising Rs 28.20 or 8.86%. The day’s low was Rs 297.25, which means the share price recovered strongly from that level and ended at the session high of Rs 346.40. The opening price was Rs 317.95, almost in line with the previous close, before the stock moved higher through the session. Turnover stood at Rs 0.54 crore, providing only a traded-value snapshot. In simple terms, Medicamen Biotech Share Price news today is centred on a verified price rise and a close at the day high.
Medicamen Biotech Ltd. (MEDICAM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 438.76 crore |
| P/E Ratio | 39.85x |
| P/B Ratio | 1.59x |
| ROE | 3.23% |
| ROCE | 5.77% |
| EPS | Rs 7.98 |
| Book Value Per Share | Rs 199.52 |
| Dividend Yield | 0.31% |
Medicamen Biotech Ltd. (MEDICAM) fundamental metrics show P/E 39.85x, P/B 1.59x, ROE 3.23%, ROCE 5.77%. These figures provide context only and are not a buy or sell signal.
Medicamen Biotech Ltd. has a market capitalisation of Rs 438.76 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 39.85x, P/B at 1.59x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 3.23% and ROCE of 5.77%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 7.98, book value per share of Rs 199.52, dividend yield of 0.31%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.74x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 39.85x |
| Benchmark Median P/E | 31.74x |
| Benchmark Average P/E | 47.98x |
| Benchmark P/E Range | 3.29x to 683.37x |
| Company P/B Ratio | 1.59x |
| Benchmark Median P/B | 3.02x |
| Company ROE | 3.23% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 5.77% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 438.76 crore |
| Benchmark Median Market Cap | Rs 750.5 crore |
Medicamen Biotech Ltd. (MEDICAM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 39.85x, which is above the benchmark median of 31.74x, a difference of +25.55%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Medicamen Biotech Ltd. (MEDICAM) has a ROE of 3.23%, which is below the benchmark median of 11.78%, a difference of -72.58%. Medicamen Biotech Ltd. (MEDICAM) has a ROCE of 5.77%, which is below the benchmark median of 13.65%, a difference of -57.73%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,41,957.5 | 36.4 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,47,576 | 83.41 | 13.81 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,89,233.01 | 84.58 | 20.55 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,11,670.55 | 24.29 | 4.07 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,10,272.68 | 32.62 | 3.13 | 11.83 | 16 |
Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 39.85x compared with the displayed peer median of 36.4x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 3.23% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 5.77% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Medicamen Biotech Ltd. (MEDICAM) has a market capitalisation of Rs 438.76 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Medicamen Biotech
- Medicamen Biotech Share Price rose 8.86% today to Rs 346.40 from Rs 318.20.
- The stock closed at the day high of Rs 346.40 after opening at Rs 317.95.
- Market capitalisation stands at Rs 438.76 crore, with turnover of Rs 0.54 crore.
- P/E is 39.85, P/B is 1.59, EPS is Rs 7.98 and book value is Rs 199.52.
- ROE is 3.23% and ROCE is 5.77%, both below the industry benchmark shown here.
About Medicamen Biotech Ltd.
Medicamen Biotech Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data does not include a deeper segment breakup, but the company is positioned within a pharmaceutical industry benchmark that includes 200 companies. For readers searching Medicamen Biotech Share Price Live or Medicamen Biotech Latest News, the important company-level context is that this is a listed healthcare business whose market capitalisation is Rs 438.76 crore.
The company’s financial profile in the supplied dataset includes a P/E of 39.85, a P/B of 1.59, ROE of 3.23%, ROCE of 5.77%, EPS of Rs 7.98, book value of Rs 199.52 and dividend yield of 0.31%. Those figures help explain why Medicamen Biotech Stock Analysis needs both price and financial context. Univest uses this company overview to frame Medicamen Biotech Share Price within the listed pharmaceutical universe, not as a standalone trading print.
Track Medicamen Biotech Share Price on Univest
Use Medicamen Biotech Ltd. (MEDICAM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Readers can track Medicamen Biotech Share Price on Univest for live share price updates, fundamental ratios, shareholding pattern, 52-week levels and market insights. Univest also helps users follow Medicamen Biotech Stock News, Medicamen Biotech Company News and Medicamen Biotech Share Price Update in one place, with a clean view of the stock’s latest price action and research context.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Medicamen Biotech Share Price rise today?
Ans. The supplied data confirms that Medicamen Biotech Share Price rose 8.86% to Rs 346.40, but it does not establish a company-specific catalyst. The move is verified through price data, opening, high, low and previous close.
What is Medicamen Biotech Share Price today?
Ans. Medicamen Biotech Share Price today is Rs 346.40. It was up Rs 28.20 from the previous close of Rs 318.20, making it one of the notable same-day gainers in today’s stock news flow.
What was the day’s high and low for Medicamen Biotech?
Ans. The stock touched a high of Rs 346.40 and a low of Rs 297.25. It opened at Rs 317.95 and finished at the day high, which defines the session’s full price range.
What is the market capitalisation of Medicamen Biotech Ltd.?
Ans. Medicamen Biotech Ltd. has a market capitalisation of Rs 438.76 crore. That places it below the same-industry median of Rs 750.5 crore in the benchmark data used for this article.
How is Medicamen Biotech valued compared with peers?
Ans. Medicamen Biotech’s P/E of 39.85 is above some peers and below others, while its P/B of 1.59 is lower than the peer set shown. Its ROE and ROCE are also below the listed peers.
What do Medicamen Biotech’s EPS and book value show?
Ans. EPS is Rs 7.98 and book value is Rs 199.52. EPS reflects earnings per share, while book value shows the accounting net worth behind each share, both of which help frame the stock’s valuation.
What does the industry benchmark say about Medicamen Biotech?
Ans. In the same-industry benchmark of 200 companies, Medicamen Biotech’s P/E is above the median but below the average. Its ROE, ROCE and market cap are all below the benchmark median values shown.
Should investors track Medicamen Biotech Share Price on Univest?
Ans. Univest lets readers follow Medicamen Biotech Share Price with live price updates, fundamental ratios, shareholding pattern and market insights. That makes it useful for tracking stock news, company context and same-day price action in one place.
